secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001171843-23-002889
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.
- Net loss $23.0M ($0.53 per share) compared to $35.6M ($0.84) in Q1 2022.
- R&D expenses decreased to $18.1M from $31.7M YoY due to wind-down of STOPS and ASO programs.
- NASH gel cap formulation selected; Phase 2 IND filing remains on track for Q4 2023.
- COVID-19 protease inhibitor CTA submitted in UK; first-in-human dosing expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/0001171843-23-002889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323002889/f8k_050423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer